Military-proven concepts of signals intelligence uncovers deep understanding of the modern consumer decision journey
Military-proven concepts of signals intelligence uncovers deep understanding of the modern patient treatment journey
Signals is proud to announce our 273% growth rate and join Deloitte's list of fast-growth companies for the second year
Through connecting the dots between unstructured data, Signals identifies 12 innovative companies impacting innovations in microbiome
As fickle consumer preferences trend towards health and wellness, is sugar poised to fall out of consumer favor?
How will advances in clinical trial design and companion diagnostics impact immunotherapy applications in oncology?
Food companies adopt personalization options in product innovation and packaging to develop deeper connections with consumers
CRISPR applications in agriculture provide valuable use cases and lessons learned as applications more towards therapeutics
What do consumers want in their wearables devices? Signals' analysis pinpoints key unmet needs and the benefits they expect to see
Why pharmaceuticals are focusing on beyond-the-pill initiatives as the next forefront of innovation in addressing patient experience
What Unilever's acquisition says about the future of direct-to-consumer business models in consumer goods and retail
See the five digital health acquisitions of 2016 that signal the future of connected healthcare services
As fickle consumer preferences trend towards health and wellness, is soda water the companies solution to declining soft drink sales?
Omnichannel tactics attempt to bridge the gap between online and offline marketing channels
Examining how fickle consumer demand has driven the soda giants' product portfolio evolution
Signals Analytics is proud to be named a 2016 Cool Vendor in R&D for Manufacturers by Gartner, Inc.
When companies turn their attention outward to unstructured data they can understand not only what exists, but what ought to be
$10 Million raised in new funding round with Qumra Capital completes Signals Analytics Series B
The miniturization of devices and decreasing cost of solutions drives the beauty device market and growth in personal home-use treatment
What sets Signals apart? Our approach to unstructured data, process for collection and unification, and proprietary models
The top four trends in diabetes technologies today coming out of the Advanced Technologies & Treatments for Diabetes Conference, in Milan, Italy
$15 Million raised in new funding round with Sequoia Capital leads Signals Analytics Series B
Signals is proud to announce our 179% growth rate and debut on Deloitte's list of fast-growth companies